Derleme
Yıl 2019,
Cilt: 7 Sayı: 3, 6 - 10, 05.04.2019
Öz
Abstract
Diabetic foot ulcers are one of the most important complications in diabetes. Although new treatment strategies have emerged, it can still threat approximately %10 dia-betic patient. Most diabetic patients have neuropathy or ischemic conditions. The main strategy is to prevent the occurrence of diabetic foot by the education of the patients.
Anahtar Kelimeler
Kaynakça
- Kaynaklar 1.Singh N, Armstrong DG, Lipsky BA. Preventing foot ulcersin patients with diabetes. JAMA. 2005 Jan 12; 293(2):217-28 2.Oyibo SO, Jude EB, Tarawneh I, Nguyen HC, Armstrong DG,Harkless LB, Boulton AJ. The effects of ulcer size and site,patient's age, sex and type and duration of diabetes on the out-come of diabetic foot ulcers. Diabet Med. 2001 Feb;18(2):133-8. 3.Economic costs of diabetes in the U.S. In 2007.American Dia-betes Association Diabetes Care. 2008 Mar; 31(3):596-615 4.Valensi P, Girod I, Baron F, Moreau-Defarges T, Guillon P.Quality of life and clinical correlates in patients with diabe-tic foot ulcers. Diabetes Metab. 2005 Jun; 31(3 Pt 1):263-71. 5.Clayton W., Jr., Elasy T. A. A review of the pathophysiology,classification, and treatment of foot ulcers in diabetic pati-ents.Clinical Diabetes. 2009;27(2):52–58 6.McNeely MJ, Boyko E, Ahroni JH. The independent contri-butions of diabetic neuropathy and vasculopathy in foot ul-ceration: how great are the risks? Diabetes Care1995;18:216–9 7.Ahmad J.The diabetic foot. Diabetes Metab Syndr. 2016 Jan-Mar;10(1):48-60 8.Schram JC, Dinh T, Vevas A. Microvascular changes in thediabetic foot. Int J Low Extreme Wounds 2006;5:149–59. 9.Lipsky BA, Berendt AR , Cornia PB ,Pile JC , Peters EJGve ark. 2012 Infectious Diseases Society of America ClinicalPractice Guideline for the Diagnosis and Treatment of Dia-betic Foot Infections Clinical Infectious Diseases2012;54(12):132–173. 10.Purandare H, Supe A. Immunmodulatory role of tinospora cor-difolia as an surgical treatment of diabetic foot ulcers: A pros-pective randomized controlled study. Indian J Med Sci2007;61:347-55 11.Robertson DD, Mueller MJ, Smith KE, Commean PK, Polg-ram T, Johnson JE. Structural changes in the forefoot of in-dividuals with diabetes and a prior plantar ulcer. J Bone Jo-int Surg Am 2002;84:1395–404. 12.Brownlee M, Aiello LP, Friedman E, Vinik AI, Nesto RW, Bo-ulton AJM. Complications of diabetes mellitus. In: Larsen R,Krokenberg HM, Melmed S, Polonsky KS, editors. Williams textboot of endocrinology. 10th ed., Philadelphia, USA: Sa-unders; 2003. p. 1560–3. 13.Sinacore DR, Withrington NC: Recognition and managementof acute neuropathic (Charcot) arthropathies of the foot andankle. J Orthop Sports Phys Ther.1999 Dec; 29(12):736-46. 14.Sommer TC, Lee TH: Charcot foot: diagnostic dilemma. AmFam Physician. 2001 Nov 1; 64(9):1591-8. 15.Keny SJ, Smith PJ, Goldschimid MG,et al. Survey of physi-cian practice behaviors related to diabetes mellitus in the USDiabeles Care 1993;16:1507-1510 16.Peters AL, Legoreta AP, Ossorio RC, Davidson MB Qualityof outpatient care provided to diabetic patient. A health ma-intenance organization experience. Diabetes Care1996,19:601-605 17.Litzelman DK, Marriott DJ, Vinicor F. The role footwear inthe prevention of foot lesions in patients with NIDDM Dia-betes Care 1997;20:156-159 18.Alzamora MT, Forés R, Baena-Díez JM, Pera G, Toran P, Sor-ribes M ve ark. PERART/ARTPER study group peripheral ar-terial disease study (PERART/ARTPER): prevalence and riskfactors in the general population.BMC Public Health. 2010Jan 27; 10():38. 19.Wagner FW. The dysvascular foot: a system for diagnosis andtreatment.Foot Ankle. 1981 Sep;2(2):64-122. 20.Armstrong DC,Lawrence AL, Harkless LB. ArmstrongDC,Lawrence AL,Validation of a diabetic wound classifica-tion system. The contribution of depth, infection, and ische-mia to risk of amputationDiabetes Care 1998;21:855-9 21.Armstrong DG, Lavery LA: Diabetic foot study consorsium.Negative pressure wound therapy after partial diabetic footamputation: a multicentre, randomised controlled trial.Lan-cet. 2005 Nov 12;366(9498):1704-10. 22.Uchi H, Igarashi A, Urabe K, et al. Clinical efficacy of ba-sicfibroblast growth factor (bFGF) for diabetic ulcer. EurJDermatol. SepeOct 2009;19:461-468 23.Andrews KL, Houdek MT, Kiemele LJ. Wound managementof chronic diabetic foot ulcers: from the basics to regenera-tive medicine. Prostht Orthot Int. 2015;39(1):29-39
Yıl 2019,
Cilt: 7 Sayı: 3, 6 - 10, 05.04.2019
Öz
Öz
Diyabetik ayak, diyabet komplikasyonları içinde en ciddi sorun yaratanlardan bir tanesidir. Diyabetik nöropati ve iskemi zemininde gelişebilen bu süreç yeni tedavi yöntemlerine karşın halen tüm diyabet hastalarının %10 yakın bir kısmını riske atmaktadır. Bu süreçte hastaların eğitimi ile diyabetik ayak oluşumunu önlemek en önemli yaklaşımdır.
Anahtar Kelimeler
Kaynakça
- Kaynaklar 1.Singh N, Armstrong DG, Lipsky BA. Preventing foot ulcersin patients with diabetes. JAMA. 2005 Jan 12; 293(2):217-28 2.Oyibo SO, Jude EB, Tarawneh I, Nguyen HC, Armstrong DG,Harkless LB, Boulton AJ. The effects of ulcer size and site,patient's age, sex and type and duration of diabetes on the out-come of diabetic foot ulcers. Diabet Med. 2001 Feb;18(2):133-8. 3.Economic costs of diabetes in the U.S. In 2007.American Dia-betes Association Diabetes Care. 2008 Mar; 31(3):596-615 4.Valensi P, Girod I, Baron F, Moreau-Defarges T, Guillon P.Quality of life and clinical correlates in patients with diabe-tic foot ulcers. Diabetes Metab. 2005 Jun; 31(3 Pt 1):263-71. 5.Clayton W., Jr., Elasy T. A. A review of the pathophysiology,classification, and treatment of foot ulcers in diabetic pati-ents.Clinical Diabetes. 2009;27(2):52–58 6.McNeely MJ, Boyko E, Ahroni JH. The independent contri-butions of diabetic neuropathy and vasculopathy in foot ul-ceration: how great are the risks? Diabetes Care1995;18:216–9 7.Ahmad J.The diabetic foot. Diabetes Metab Syndr. 2016 Jan-Mar;10(1):48-60 8.Schram JC, Dinh T, Vevas A. Microvascular changes in thediabetic foot. Int J Low Extreme Wounds 2006;5:149–59. 9.Lipsky BA, Berendt AR , Cornia PB ,Pile JC , Peters EJGve ark. 2012 Infectious Diseases Society of America ClinicalPractice Guideline for the Diagnosis and Treatment of Dia-betic Foot Infections Clinical Infectious Diseases2012;54(12):132–173. 10.Purandare H, Supe A. Immunmodulatory role of tinospora cor-difolia as an surgical treatment of diabetic foot ulcers: A pros-pective randomized controlled study. Indian J Med Sci2007;61:347-55 11.Robertson DD, Mueller MJ, Smith KE, Commean PK, Polg-ram T, Johnson JE. Structural changes in the forefoot of in-dividuals with diabetes and a prior plantar ulcer. J Bone Jo-int Surg Am 2002;84:1395–404. 12.Brownlee M, Aiello LP, Friedman E, Vinik AI, Nesto RW, Bo-ulton AJM. Complications of diabetes mellitus. In: Larsen R,Krokenberg HM, Melmed S, Polonsky KS, editors. Williams textboot of endocrinology. 10th ed., Philadelphia, USA: Sa-unders; 2003. p. 1560–3. 13.Sinacore DR, Withrington NC: Recognition and managementof acute neuropathic (Charcot) arthropathies of the foot andankle. J Orthop Sports Phys Ther.1999 Dec; 29(12):736-46. 14.Sommer TC, Lee TH: Charcot foot: diagnostic dilemma. AmFam Physician. 2001 Nov 1; 64(9):1591-8. 15.Keny SJ, Smith PJ, Goldschimid MG,et al. Survey of physi-cian practice behaviors related to diabetes mellitus in the USDiabeles Care 1993;16:1507-1510 16.Peters AL, Legoreta AP, Ossorio RC, Davidson MB Qualityof outpatient care provided to diabetic patient. A health ma-intenance organization experience. Diabetes Care1996,19:601-605 17.Litzelman DK, Marriott DJ, Vinicor F. The role footwear inthe prevention of foot lesions in patients with NIDDM Dia-betes Care 1997;20:156-159 18.Alzamora MT, Forés R, Baena-Díez JM, Pera G, Toran P, Sor-ribes M ve ark. PERART/ARTPER study group peripheral ar-terial disease study (PERART/ARTPER): prevalence and riskfactors in the general population.BMC Public Health. 2010Jan 27; 10():38. 19.Wagner FW. The dysvascular foot: a system for diagnosis andtreatment.Foot Ankle. 1981 Sep;2(2):64-122. 20.Armstrong DC,Lawrence AL, Harkless LB. ArmstrongDC,Lawrence AL,Validation of a diabetic wound classifica-tion system. The contribution of depth, infection, and ische-mia to risk of amputationDiabetes Care 1998;21:855-9 21.Armstrong DG, Lavery LA: Diabetic foot study consorsium.Negative pressure wound therapy after partial diabetic footamputation: a multicentre, randomised controlled trial.Lan-cet. 2005 Nov 12;366(9498):1704-10. 22.Uchi H, Igarashi A, Urabe K, et al. Clinical efficacy of ba-sicfibroblast growth factor (bFGF) for diabetic ulcer. EurJDermatol. SepeOct 2009;19:461-468 23.Andrews KL, Houdek MT, Kiemele LJ. Wound managementof chronic diabetic foot ulcers: from the basics to regenera-tive medicine. Prostht Orthot Int. 2015;39(1):29-39
Toplam 1 adet kaynakça vardır.
Ayrıntılar
| Birincil Dil | Türkçe |
|---|---|
| Bölüm | Makaleler 1 |
| Yazarlar | |
| Yayımlanma Tarihi | 5 Nisan 2019 |
| Yayımlandığı Sayı | Yıl 2019 Cilt: 7 Sayı: 3 |
